Framework Collaboration Agreement with Novartis Across Multiple Drug Programmes
BenevolentAI announced that it has signed a Framework Collaboration Agreement with Novartis Pharma AG (“Novartis”) to leverage BenevolentAI’s technology platform to interrogate clinical trial and experimental data. This collaboration programme will be led by the Precision Medicine Team within Novartis Global Drug Development. The two companies will investigate indications and responder group(s) for oncology assets currently in clinical development.
Under the terms of the agreement, BenevolentAI will apply its technology designed to enable better data-driven decisions to find new ways to treat disease and personalise drugs for patients. The Benevolent Platform® ingests molecular, clinical, pharmacological data and scientific literature, to derive contextual relationships in the data between genes, diseases, drugs and biological pathways leading to the proposal of novel/optimal drug targets. The Platform supports scientists in the design and optimisation of the right drug molecule for a unique patient population.
Joanna Shields, CEO of BenevolentAI said,
“We’re excited to be entering into this important collaboration with Novartis. While the same drug may be prescribed for all patients diagnosed with a disease, often the underlying cause of the disease varies from patient to patient. Consequently, many experience little therapeutic benefit. This initial project with Novartis in oncology will see the application of our AI and machine learning technology to stratify patients and gain a better understanding of patient and disease heterogeneity to more precisely target medicines for patients who need them.”
BenevolentAI is HQ’d in London with a research facility in Cambridge (UK) and further offices in New York and Belgium. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson’s, Ulcerative Colitis and Sarcopenia.